ArticleVeterinary immunology and immunopathology2009
Development of cell-mediated immunity to porcine circovirus type 2 (PCV2) in caesarean-derived, colostrum-deprived piglets.
Article in Veterinary immunology and immunopathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 94 citations in OpenAlex.
- Evaluation of the efficacy of a novel porcine circovirus type 2 synthetic peptide vaccine.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2018Trial
- Development of porcine circovirus 2 (PCV2) open reading frame 2 DNA vaccine with different adjuvants and comparison with commercial PCV2 subunit vaccine in an experimental challenge.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2017Trial
- Effect of sow vaccination against porcine circovirus type 2 (PCV2) on virological profiles in herds with or without PCV2 systemic disease.The Canadian veterinary journal = La revue veterinaire canadienne · 2016Trial
- Impact of maternally derived immunity on piglets' immune response and protection against porcine circovirus type 2 (PCV2) after vaccination against PCV2 at different age.BMC veterinary research · 2016Trial
- Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge.BMC veterinary research · 2012Trial
- Porcine Peripheral Blood Mononuclear Cells (PBMCs): Methods of Isolation, Cryopreservation, and Translational Applications in Human Studies.Journal of clinical medicine · 2025Review
- Cellular immune signatures and differences of four porcine circovirus type 2 vaccines to heterologous PCV2d infection.NPJ vaccines · 2025Article
- Non-Compromised Efficacy of the First Commercial Ready-to-Use Genotype 2d Porcine Circovirus Type 2 andViruses · 2025Article
- A field evaluation of a new porcine circovirus type 2d and Mycoplasma hyopneumoniae bivalent vaccine in herds suffering from subclinical PCV2d infection and enzootic pneumonia.Veterinary medicine and science · 2024Article
- The porcine circovirus 3 humoral response: characterization of maternally derived antibodies and dynamic following experimental infection.Microbiology spectrum · 2024Article
- Article
- Article
- Efficacy of a novel bivalent vaccine containing porcine circovirus type 2d andFrontiers in veterinary science · 2023Article
- Surface Display ofFrontiers in immunology · 2022Article
- Maternally Derived Antibody Levels Influence on Vaccine Protection against PCV2d Challenge.Animals : an open access journal from MDPI · 2021Article
- Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b andFrontiers in veterinary science · 2021Article
- Porcine Circovirus 2 Genotypes, Immunity and Vaccines: Multiple Genotypes but One Single Serotype.Pathogens (Basel, Switzerland) · 2020Review
- Efficacy comparison of commercial porcine circovirus type 2 (PCV2) andCanadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2020Article
- Construction of polycistronic baculovirus surface display vectors to express the PCV2 Cap(d41) protein and analysis of its immunogenicity in mice and swine.Veterinary research · 2020Article
- Incorporation of a truncated form of flagellin (TFlg) into porcine circovirus type 2 virus-like particles enhances immune responses in mice.BMC veterinary research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interaction between porcine circovirus type 2 (PCV2) and the pig immune system has been suggested to be a determinant event for the pathogenesis of postweaning multisystemic wasting syndrome (PMWS). To gain insight into the host immune mechanisms developed upon PCV2 infection, early innate and adaptive immune responses were examined in 1-week-old, caesarean-derived, colostrum-deprived piglets using a subclinical infection model of PCV2 in combination with lipopolysaccharide (LPS) as a potential immunostimulation factor. The use of LPS did not show any significant effect on the course of PCV2 infection, nor did in the evolution of the immunological parameters evaluated. Ex vivo responses were detected as early as 1 day post-infection (PI) and consisted of an elevation of the plasmatic levels of interleukin (IL)-8 in PCV2-inoculated pigs followed by an increase on plasmatic IFN-alpha at day 5 PI. Regarding IL-10, only one PCV2-inoculated pig was positive (day 7 PI); this pig was the only one in which viremia persisted until the end of the study. In vitro cytokine determination showed that, regardless of the treatment administrated to the pigs, an IL-10 release was observed when peripheral blood mononuclear cells (PBMC) cultures were stimulated with PCV2. Seroconvertion to PCV2 measured by an immunoperoxidase monolayer assay (IPMA) occurred between 7 and 14 days PI, whereas neutralizing antibodies (NA) did not appear until day 29 PI. PCV2 DNA was first detected in serum at day 7 PI, reaching the peak of viremia between days 14 and 21 PI, followed by a drop in viral load that was found coincident with the appearance of PCV2-specific IFN-gamma-secreting cells (PCV2-IFN-gamma-SC) and NA. Results from the present work suggest that viral clearance might be mediated by the development of PCV2-IFN-gamma-SC in contribution to the PCV2-specific NA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.